<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00241410</url>
  </required_header>
  <id_info>
    <org_study_id>OralvacB2MPL103</org_study_id>
    <secondary_id>EudraCT No.: 2005-004095-20</secondary_id>
    <nct_id>NCT00241410</nct_id>
  </id_info>
  <brief_title>Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen</brief_title>
  <official_title>Investigation of the Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergy Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergy Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and tolerability of different dose combinations of MPL and grass pollen allergen and&#xD;
      to identify the highest combinations of MPL and grass pollen allergen which is safe.&#xD;
&#xD;
      Pharmacodynamics and efficacy of MPL and grass pollen allergen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective of this trial is to demonstrate the safety and tolerability of different dose&#xD;
      combinations of MPL and grass pollen allergen and to identify the highest combination of MPL&#xD;
      and grass pollen allergen which is safe.&#xD;
&#xD;
      Other objectives are to investigate the pharmacodynamics and efficacy of MPL and grass pollen&#xD;
      allergen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events,</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>allergic reactions/symptomatology</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Type I Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 consecutive groups, dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 consecutive groups</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OralvacB2MPL</intervention_name>
    <description>Comparison of different dosages of drug</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>MPL and/or grass pollen allergen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects, between 18 and 65 years.&#xD;
&#xD;
          -  BMI 18 - 32 kg/m².&#xD;
&#xD;
          -  Positive skin prick test (wheal&gt;4mm) with grasses pollen allergen extract.&#xD;
&#xD;
          -  Specific IgE to grass pollen allergens by RAST (or equivalent test) ≥ class 2.&#xD;
&#xD;
          -  Women of childbearing potential must be using a medically acceptable method of birth&#xD;
             control and have a negative β-HCG pregnancy test result at screening and Day 1&#xD;
             predose. Male subjects must also agree to use the double barrier method of&#xD;
             contraception during the study.&#xD;
&#xD;
          -  In the opinion of the investigator, each subject will be able to understand verbal and&#xD;
             written instructions and competent to follow these instructions.&#xD;
&#xD;
          -  Subjects must read, understand, sign, and date the written informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive human immunodeficiency virus (HIV)-test, acute or chronic hepatitis B/C&#xD;
             (except vaccination titer).&#xD;
&#xD;
          -  Positive drug screen.&#xD;
&#xD;
          -  Positive alcohol breath test.&#xD;
&#xD;
          -  Known or suspected drug or alcohol abuse.&#xD;
&#xD;
          -  History of clinically significant cardiovascular (especially heart failure or&#xD;
             pulmonary insufficiency), pulmonary (except for asthma), hepatic, renal,&#xD;
             gastrointestinal, hematologic, endocrine, dermatological, or metabolic disease within&#xD;
             the last 2 years. A clinically significant disease is defined as a disease which, in&#xD;
             the opinion of the investigator, may either put the subject at risk because of&#xD;
             participation in the trial or a disease which may influence the results of the trial&#xD;
             or the subject's eligibility to participate in the trial.&#xD;
&#xD;
          -  Clinically significant abnormalities on pre-study physical examination, vital signs,&#xD;
             electrocardiogram (ECG), or laboratory tests; acute illness within 7 days before the&#xD;
             screening visit.&#xD;
&#xD;
          -  History of allergy to all-season allergens and / or history of allergy to other&#xD;
             seasonal allergens than grass pollen which might interfere with period of trial&#xD;
             conduct&#xD;
&#xD;
          -  History of a major psychiatric disorder such as schizophrenia, other psychotic&#xD;
             symptomatology, major depressive disorder, or suicide attempt within the past 5 years;&#xD;
             history of alcohol or drug abuse within the past year; history or evidence of a&#xD;
             progressive central nervous system (CNS) disease, lesion, or encephalopathy.&#xD;
&#xD;
          -  History of malignancy within the past 2 years; with the exception of basal cell&#xD;
             carcinoma.&#xD;
&#xD;
          -  Acute or subacute atopic dermatitis.&#xD;
&#xD;
          -  Periodontitis, gingivitis, gingival bleeding or other mucosal disorders in the oral&#xD;
             cavity or planned tooth extraction during the course of the study.&#xD;
&#xD;
          -  Secondary changes of the reactive organs (e.g., emphysema, bronchiectasis).&#xD;
&#xD;
          -  Auto-immune disease (e.g., of liver, kidney, thyroid, nervous system) rheumatoid&#xD;
             diseases.&#xD;
&#xD;
          -  Immunodeficiencies (e.g., by immunosuppressive agents).&#xD;
&#xD;
          -  Therapy with β-blockers.&#xD;
&#xD;
          -  Therapy with antihistamines less than three days prior to Day 1 .&#xD;
&#xD;
          -  Therapy with corticosteroids (except hormonal contraceptives) four weeks prior to Day&#xD;
             1 (with the exception of local steroids, which must be terminated from three days&#xD;
             prior to Day 1).&#xD;
&#xD;
          -  Vaccinations in the last three months.&#xD;
&#xD;
          -  Unable to comply with recommended therapy-free interval for specified medications&#xD;
             prior to skin prick test.&#xD;
&#xD;
          -  Current diseases with a pathogenesis interfering with the immune response and diseases&#xD;
             for which medication has been given, which could influence the results of this study.&#xD;
&#xD;
          -  Acute or chronic infection.&#xD;
&#xD;
          -  Already undergone hyposensitization therapy with grass pollen allergens within the&#xD;
             last three years.&#xD;
&#xD;
          -  Use of MPL-containing products within the last 12 months or allergy / hypersensitivity&#xD;
             to MPL.&#xD;
&#xD;
          -  Pregnancy or breast-feeding.&#xD;
&#xD;
          -  Use of any investigational drug or medical device within 30 days prior to the&#xD;
             screening visit.&#xD;
&#xD;
          -  A handicap that would prevent compliance with the study procedures or proper reporting&#xD;
             of adverse events.&#xD;
&#xD;
          -  Subjects who smoke more than 10 cigarettes a day&#xD;
&#xD;
          -  Subjects unable to conduct nasal washes and comply with nasal challenge tests&#xD;
             according to the instruction of the investigator&#xD;
&#xD;
          -  Total flow during rhinomanometry with vehicle solution is more than 40% lower than&#xD;
             total flow obtained with blank measurement (note: this exclusion criteria does not&#xD;
             apply to the screening visit but to nasal challenge test performed on Day 1 predose)&#xD;
&#xD;
          -  In the opinion of the investigator, unable to complete the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Timmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRS Clinical Research Services Mannheim GmbH, Grenadierstraße 1, 68167 Mannheim, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRS Clinical Research Services Mannheim GmbH</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>October 17, 2005</study_first_submitted>
  <study_first_submitted_qc>October 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2005</study_first_posted>
  <last_update_submitted>June 16, 2010</last_update_submitted>
  <last_update_submitted_qc>June 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jutta Amersdorffer</name_title>
    <organization>Allergy Therapeutics (UK) Ltd.</organization>
  </responsible_party>
  <keyword>Allergy</keyword>
  <keyword>Specific Immunotherapy</keyword>
  <keyword>Sublingual Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Hypersensitivity, Immediate</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

